Blau Farmacêutica: 33% revenue growth and margin expansion in 1Q26, with zero leverage and strong cash position

About this update from Blau Farmaceutica Sa

Revenue grew 33% year-over-year in 1Q26, with strong gains in gross and EBITDA margins and zero leverage. Growth was led by the hospital segment and mature products, while new launches and production lines are expected to drive further gains in 2026.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Blau Farmaceutica Sa